The Food and Drug Administration (FDA) plans to hold a public hearing on May 31 in Maryland to explore issues around products containing cannabis or cannabis-derived compounds such as cannabidiol (CBD).
The hearing is to gather “scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of products containing cannabis or cannabis-derived compounds,” according to a notice scheduled to be published April 3 in the Federal Register.
Products regulated by FDA -- including conventional food, cosmetics, drugs and supplements -- are being marketed with varying amounts of CBD, a compound that derives from both hemp and marijuana and is said to promote myriad health benefits.
Click here to read the complete article
Josh Long ~ SupermarketNews.com ~
